The Strategic Role of Biomarkers in Drug Discovery and Clinical Trials Every decision in drug development carries weight. The ...

Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development BOSTON--(BUSINESS WIRE)-- Genialis, the RNA biomarker company, ...

The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...

Two overarching goals tied to a futuristic vision of personalized medicine are to maximize individually derived benefits from available therapeutic drugs or biological agents and identify a reliable ...

SAN FRANCISCO, Jan 13 () - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug ...

New exploratory findings demonstrate that in responders with IGFBP7 biomarker decline, CNM-Au8 30mg was strongly associated ...

Ibex's high-performance AI platform-already deployed across more than 50 health systems worldwide and used in collaboration ...

Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery market ...